| Bioactivity | PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM[1]. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM[2]. | ||||||||||||
| Target | IC50 : 2.6 µM (Papain-like protease (PLpro)); 5.0 µM (SARS-CoV-2 PLpro)EC50: 21.0 µM (SARS-CoV-2 PLpro) | ||||||||||||
| Invitro | PLpro inhibitor is a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). PLpro inhibitor was found to have IC50 value of 2.6 μM. PLpro inhibitor display significant antiviral activity with EC50 values of 13.1 μM, without toxicity up to the highest concentration tested. Notably, the increasing antiviral potency correlates with the in vitro inhibition of PLpro, suggesting that the compounds work directly on the enzyme in cells[1][3]. | ||||||||||||
| Name | PLpro inhibitor | ||||||||||||
| CAS | 1093070-14-4 | ||||||||||||
| Formula | C22H22N2O2 | ||||||||||||
| Molar Mass | 346.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24. [2]. http://www.google.com/patents/WO2010022355A1cl=en [3]. Brendan T Freitas, et al. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect Dis. 2020 May 19. |
PLpro inhibitor
CAS: 1093070-14-4 F: C22H22N2O2 W: 346.42
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM. PLpro inhibitor inhibits
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.